Bain and Cinven seek full control over Stada

摘要

Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved offer to minority shareholders as they seek to take full control of the German generics and OTC specialist and delist the company. The private-equity firms said they intended to launch a public delisting tender offer for the remaining 35% of Stada’s shares not held by their Nidda Healthcare holding vehicle.